Clinical significance of human atrial natriuretic peptide and cyclic GMP in patients on chronic hemodialysis. Usefulness in determination of dry body weight in patients who have a high cardiothoracic ratio.

Q: What does this research mean for the field?

Plasma human atrial natriuretic peptide (hANP) and cyclic GMP (cGMP) concentrations are useful indicators for determining dry weight in chronic hemodialysis patients, particularly for identifying patients with a high cardiothoracic ratio who do not require further fluid removal. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Masashi Mizuno; Yasuhiko Ito; Takashi Suzuki; Mika Baba; Shizunori Ichida; Nobuo Sakamoto; Seiichi Matsuo

doi:10.4009/jsdt.27.1295

January 1, 1994Nihon Toseki Igakkai ZasshiOpen Access

Clinical significance of human atrial natriuretic peptide and cyclic GMP in patients on chronic hemodialysis. Usefulness in determination of dry body weight in patients who have a high cardiothoracic ratio.

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does the measurement of plasma hANP and cGMP improve the determination of dry weight in maintenance hemodialysis patients with a high cardiothoracic ratio?

Structured PICO

Does the measurement of plasma hANP and cGMP improve the determination of dry weight in maintenance hemodialysis patients with a high cardiothoracic ratio?

P

Population

Maintenance hemodialysis patients, particularly those with a persistently high cardiothoracic ratio (CTR ≥50%).

I

Intervention

Measurement of plasma human atrial natriuretic peptide (hANP) and cyclic GMP (cGMP) before and after hemodialysis.

O

Outcome

Utility of hANP and cGMP in determining dry weight (DW) and their correlation with echocardiographic parameters of volume overload (LVDd, LVDs, EF).surrogate

Plasma hANP and cGMP are useful biomarkers for assessing volume overload and determining dry weight in hemodialysis patients, preventing unnecessary fluid removal in those with a high cardiothoracic ratio but normal biomarker levels.

Implication

hANP and cGMP may aid dry weight assessment in high-CTR hemodialysis patients; hypothesis-generating and requires prospective validation.

Abstract

維持血液透析患者に血漿心房性ナトリウム利尿ペプチド (hANP)・cyclic GMP (cGMP) を測定して, dry weight (DW) 決定に意義があるか, また特に心胸比 (CTR) が常に高値の患者のDW決定に有用かを検討した. 結果は, 1. cGMPは, 透析前31.4±15.9mol/ml (平均±標準偏差), 透析後10.4±5.4pmol/mlで有意に下降し, hANPと同様にDWの指標になると考えられた. 2. 心臓超音波所見上, 透析前後でhANPの血中濃度と左室拡張末期径 (LVDd) や左室収縮末期径 (LVDs) の間に, それぞれ相関がみられ, また左室駆出率 (EF) との間には透析前後でそれぞれ負の相関が認められ, 容量負荷を反映していた. 3. CTRが50%以上でも, 身体所見・心臓超音波検査より容量負荷がみられず, かつ透析後のhANP濃度が正常域となる群が存在して, これらの患者に対し, さらなる除水およびDW低下は不要であると考えた. よって, 血漿hANP濃度が透析前CTR高値群のDW決定において有用であることが示唆された. また, cGMPもhANPと同様に有用性が認められた.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mizuno et al. (1994) studied this question.

synapsesocial.com/papers/6a1bec0626cb5670aa9d1d6d https://doi.org/10.4009/jsdt.27.1295

View Full Paper

Ask AI

Bookmark

Share

Clinical significance of human atrial natriuretic peptide and cyclic GMP in patients on chronic hemodialysis. Usefulness in determination of dry body weight in patients who have a high cardiothoracic ratio.

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Clinical significance of human atrial natriuretic peptide and cyclic GMP in patients on chronic hemodialysis. Usefulness in determination of dry body weight in patients who have a high cardiothoracic ratio.

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Nihon Toseki Igakkai Zasshi

Keep reading

More related papers

More from Nihon Toseki Igakkai Zasshi